CURRENT ISSUE Current Issue Cover
VOL 9 • NO 3 APR 2018
 
Section Seperator

TODAY'S NEWS

Addition of Pazopanib to Paclitaxel in P...

In a phase II trial reported in JAMA Oncology, Ric...

Dual HER2 Inhibition Plus Aromatase Inhi...

The phase III ALTERNATIVE trial demonstrated a pro...

FDA Grants Breakthrough Therapy Designat...

On December 21, the U.S. Food and Drug Administrat...

Activity of Hypoxia-Inducible Factor-2α ...

In a phase I trial reported in the Journal of Clin...

FDA Accepts sNDA, Grants Priority Review...

On December 22, the U.S. Food and Drug Administrat...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Neratinib for Extended Anti-HER2 Therapy

Neratinib (Nerlynx) is now available for the treatment of HER2–positive early breast cancer...

Targeted Therapies in the Management of NSCLC

Advances in tumor genetics and molecular biology created the potential to identify mutations...

Mismatch Repair Genes Drive Lynch Syndrome

The prevalence of Lynch syndrome (previously known as hereditary nonpolyposis colorectal cancer [HNPCC])...

Patients With Urothelial Carcinomas of the Bladder

Advances in treatment, including the successes achieved recently with immunotherapy, are improving outcomes...

Optimizing Outcomes for Patients With STS

Soft-tissue sarcomas comprise a heterogeneous group of tumors arising from transformation of mesenchymal-origin cells...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

Long-Term Outcomes With Neoadjuvant vs A...

A meta-analysis reported in <em>The Lancet O...

Addition of PEGPH20 to Nab-Paclitaxel/Ge...

In a phase II study reported in the <em>Jour...

Venetoclax in Chronic Lymphocytic Leukem...

An interim analysis of a phase II trial reported b...

FDA Updates Nilotinib Label With Informa...

On December 22, the U.S. Food and Drug Administrat...

FDA Clears Stereotactic Radiotherapy Sys...

On December 22, the U.S. Food and Drug Administrat...

More Highlights More Highlights
Section Seperator

LATEST TWEETS







More Tweets More Tweets
 
Section Seperator
Section Seperator
 
 
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here